GDF-15 Predicts Depressive Symptoms in Adults Aged 72 and Older

Deciphering the Biological Heterogeneity of Late-Life Depression

The global burden of mental health disorders often follows distinct chronological patterns, with the peak age of onset for mood disorders typically occurring in early adulthood [1]. However, the clinical presentation and underlying pathophysiology of depression in older adults are frequently complicated by systemic inflammation and the presence of comorbid somatic conditions [2]. While the gut-brain axis and various metabolic pathways have been implicated in the etiology of major depressive disorder, consistent biological markers remain elusive due to significant variability in study designs and patient populations [3]. Clinicians increasingly recognize that structural factors and chronic stressors also contribute to the risk of exhaustion and mental health decline across the lifespan [4]. A study published in the Journal of Psychiatric Research now offers specific insights into how growth differentiation factor 15 (GDF-15), a protein associated with cellular stress and aging, may track with depressive symptoms differently as patients age.

Longitudinal Assessment of Serum GDF-15 and Mood

The researchers conducted a population-based study to examine both cross-sectional and longitudinal associations between growth differentiation factor 15 (GDF-15) and symptoms of depression and anxiety. To establish a baseline, GDF-15 levels were measured once from fasting blood samples using an electrochemiluminescence immunoassay (a highly sensitive laboratory technique that uses light-emitting chemical reactions to quantify protein concentrations). The study followed participants over a mean interval of 6.3 years (± 5.7 months), providing a robust longitudinal window to observe how this protein, which typically increases with age and systemic inflammation, correlates with mental health outcomes over time. This long-term tracking is particularly relevant for clinicians managing chronic mood disorders, as it helps distinguish transient emotional fluctuations from persistent biological trends.

Age-Dependent Divergence in Biomarker Correlation

Growth differentiation factor 15 (GDF-15) is a protein that is upregulated with aging, inflammation, and various somatic diseases. While emerging evidence suggests that GDF-15 may also be associated with depression and anxiety, the researchers found that its relationship with mood is complex and highly dependent on patient age. Multiple regression models (statistical tools used to understand the relationship between multiple variables while controlling for confounding factors) revealed a significant negative association between GDF-15 levels and depressive symptoms at both baseline (p = .032, Adjusted R2 = 0.279) and follow-up (p = .040, Adjusted R2 = 0.293). The Adjusted R2 value indicates that the model accounts for approximately 28 to 29 percent of the variance in depression scores. Despite these findings in depressive symptoms, no significant association emerged between GDF-15 levels and anxiety symptoms, suggesting the protein may be a more specific marker for depressive pathology rather than general emotional distress.

Clinical Specificity and Diagnostic Implications

The clinical utility of GDF-15 as a biomarker is clarified by the role of age as a moderator (a variable that changes the strength or direction of the effect between the protein and mood symptoms). The researchers identified a significant GDF-15 x age interaction at both baseline (p = .019) and follow-up (p = .030). This interaction indicates that the correlation between serum protein levels and depression scores is not uniform across the lifespan. While no association between GDF-15 and depressive symptoms was identified in younger adults, a distinct and clinically relevant pattern emerged as participants aged into their eighth decade. In the geriatric population, the direction of the association reversed, with the protein becoming a predictor of increased symptom burden. Older participants showed a significant positive association between GDF-15 and depressive symptoms at baseline (≥ 71.66 years, p = .050) and at the six-year follow-up (≥ 73.51 years, p = .050). These data indicate that higher GDF-15 predicts higher depression scores in adults aged 72 years and older, whereas the protein lacks predictive value for mood in younger cohorts. For the practicing physician, these findings suggest that GDF-15 may serve as a specific biological indicator of late-life depression, potentially reflecting the intersection of systemic inflammation and age-related neurobiological changes.

References

1. Solmi M, Raduà J, Olivola M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Molecular Psychiatry. 2021. doi:10.1038/s41380-021-01161-7

2. Cryan JF, O’Riordan KJ, Cowan CS, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019. doi:10.1152/physrev.00018.2018

3. Cheung S, Goldenthal A, Uhlemann A, Mann JJ, Miller JM, Sublette ME. Systematic Review of Gut Microbiota and Major Depression. Frontiers in Psychiatry. 2019. doi:10.3389/fpsyt.2019.00034

4. Aronsson G, Theorell T, Grape T, et al. A systematic review including meta-analysis of work environment and burnout symptoms. BMC Public Health. 2017. doi:10.1186/s12889-017-4153-7